Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
Adenocarcinoma
/ drug therapy
Adult
Aged
Aged, 80 and over
ErbB Receptors
/ antagonists & inhibitors
Female
High-Throughput Nucleotide Sequencing
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
/ therapeutic use
Treatment Outcome
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
10
04
2018
revised:
06
06
2018
accepted:
10
07
2018
pubmed:
27
7
2018
medline:
14
4
2020
entrez:
27
7
2018
Statut:
ppublish
Résumé
Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has not been explored. We identified all patients with metastatic Among 153 patients with TMB is negatively associated with clinical outcomes in metastatic patients with
Identifiants
pubmed: 30045933
pii: 1078-0432.CCR-18-1102
doi: 10.1158/1078-0432.CCR-18-1102
pmc: PMC6347551
mid: NIHMS1500234
doi:
Substances chimiques
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1063-1069Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA020449
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009207
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2018 American Association for Cancer Research.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44
pubmed: 16467097
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Nat Rev Cancer. 2010 Nov;10(11):760-74
pubmed: 20966921
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
J Clin Oncol. 2012 Jun 10;30(17):2063-9
pubmed: 22547605
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Cancer Res. 2004 Dec 15;64(24):8919-23
pubmed: 15604253
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Nat Genet. 2017 Dec;49(12):1693-1704
pubmed: 29106415
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Clin Cancer Res. 2018 Jul 1;24(13):3108-3118
pubmed: 29530932
J Clin Oncol. 2005 Oct 1;23(28):6829-37
pubmed: 15998907
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700